These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 32870235)
41. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer? Alany RG Pharm Dev Technol; 2020 Jul; 25(6):649. PubMed ID: 32423342 [No Abstract] [Full Text] [Related]
42. Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust. Trogen B; Oshinsky D; Caplan A JAMA; 2020 Jun; 323(24):2460-2461. PubMed ID: 32453392 [No Abstract] [Full Text] [Related]
43. Hydroxychloroquin for COVID-19 Why was so much hype? Pahlajani D J Assoc Physicians India; 2020 Aug; 68(8):94-96. PubMed ID: 32738852 [No Abstract] [Full Text] [Related]
44. Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical? Allam MF; Andraous F Cent Eur J Public Health; 2020 Sep; 28(3):246-247. PubMed ID: 32997483 [No Abstract] [Full Text] [Related]
45. Emergence of novel coronavirus and progress toward treatment and vaccine. Khan MM; Noor A; Madni A; Shafiq M Rev Med Virol; 2020 Jul; 30(4):e2116. PubMed ID: 32495979 [TBL] [Abstract][Full Text] [Related]
46. G20 leaders must answer to COVID-19. Atkinson C Science; 2020 Apr; 368(6487):111. PubMed ID: 32273441 [No Abstract] [Full Text] [Related]
48. Against pandemic research exceptionalism. London AJ; Kimmelman J Science; 2020 May; 368(6490):476-477. PubMed ID: 32327600 [No Abstract] [Full Text] [Related]
49. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence. Cairoli E; Espinosa G Med Clin (Barc); 2020 Aug; 155(3):134-135. PubMed ID: 32425245 [No Abstract] [Full Text] [Related]
50. The coronavirus outbreak could make it quicker and easier to trial drugs. Ledford H Nature; 2020 Jun; 582(7811):172. PubMed ID: 32504019 [No Abstract] [Full Text] [Related]
51. Audio Interview: Diagnosis and Early Treatment of Covid-19. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 Jun; 382(23):e103. PubMed ID: 32492326 [No Abstract] [Full Text] [Related]
52. COVID-19: Therapeutics and Their Toxicities. Chary MA; Barbuto AF; Izadmehr S; Hayes BD; Burns MM J Med Toxicol; 2020 Jul; 16(3):284-294. PubMed ID: 32356252 [TBL] [Abstract][Full Text] [Related]
53. No Easy Answers in Allocating Unapproved COVID-19 Drugs Outside Clinical Trials. Webb J; Shah L; Lynch HF Am J Bioeth; 2020 Sep; 20(9):W1-W4. PubMed ID: 32840448 [No Abstract] [Full Text] [Related]
54. Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. Ison MG; Wolfe C; Boucher HW JAMA; 2020 Jun; 323(23):2365-2366. PubMed ID: 32407438 [No Abstract] [Full Text] [Related]
55. COVID-19: The Need for Immunoprevention at Industrial Scale. Halstead SB Am J Trop Med Hyg; 2020 Jun; 102(6):1151. PubMed ID: 32274985 [No Abstract] [Full Text] [Related]
56. Keeping track of the SARS-CoV-2 vaccine pipeline. Parker EPK; Shrotri M; Kampmann B Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290 [TBL] [Abstract][Full Text] [Related]
57. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Taccone FS; Gorham J; Vincent JL Lancet Respir Med; 2020 Jun; 8(6):539-541. PubMed ID: 32304640 [No Abstract] [Full Text] [Related]
58. COVID-19: Small-Molecule Clinical Trials Landscape. Ferreira LLG; Andricopulo AD Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824 [No Abstract] [Full Text] [Related]
59. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Jakhar D; Kaur I Nat Med; 2020 May; 26(5):632. PubMed ID: 32269358 [No Abstract] [Full Text] [Related]